# Chronic Inflammatory Demyelinating Polyneuropathy FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/chronic-inflammatory-demyelinating-polyneuropathy

> 6 upcoming FDA catalysts in chronic Inflammatory Demyelinating Polyneuropathy: riliprubart (SNY) on Jul to Oct 2027 (topline data readout); riliprubart (SNY) on July 2027 (primary completion); imeroprubart (IMVT) on August 2028 (primary completion); imeroprubart (IMVT) on Aug to Nov 2028 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 16, 2026 | [Batoclimab primary completion](https://sec-api.dev/pdufa/batoclimab) | IMVT | Chronic Inflammatory Demyelinating Polyneuropathy | withdrawn | "NCT07188844 (An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-07-16 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07188844)) |
| July 20, 2026 | [Batoclimab 680 milligrams (mg) subcutaneous (sc) weekly primary completion](https://sec-api.dev/pdufa/batoclimab-680-milligrams-mg-subcutaneous-sc-weekly) | IMVT | Chronic Inflammatory Demyelinating Polyneuropathy | withdrawn | "NCT05581199 (To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-07-20 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05581199)) |
| Jul to Oct 2027 | [Riliprubart topline data readout](https://sec-api.dev/pdufa/riliprubart) | SNY | Chronic Inflammatory Demyelinating Polyneuropathy | scheduled | "NCT06290141 (A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06290141)) |
| July 2027 | [Riliprubart primary completion](https://sec-api.dev/pdufa/riliprubart) | SNY | Chronic Inflammatory Demyelinating Polyneuropathy | scheduled | "NCT06290141 (A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06290141)) |
| August 2028 | [Imeroprubart primary completion](https://sec-api.dev/pdufa/imeroprubart) | IMVT | Chronic Inflammatory Demyelinating Polyneuropathy | scheduled | "NCT07032662 (Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07032662)) |
| Aug to Nov 2028 | [Imeroprubart topline data readout](https://sec-api.dev/pdufa/imeroprubart) | IMVT | Chronic Inflammatory Demyelinating Polyneuropathy | scheduled | "NCT07032662 (Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07032662)) |
| Dec 2028 to Mar 2029 | [Claseprubart topline data readout](https://sec-api.dev/pdufa/claseprubart) | DNTH | Chronic Inflammatory Demyelinating Polyneuropathy | scheduled | "NCT06858579 (A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Dianthus Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06858579)) |
| December 2028 | [Claseprubart primary completion](https://sec-api.dev/pdufa/claseprubart) | DNTH | Chronic Inflammatory Demyelinating Polyneuropathy | scheduled | "NCT06858579 (A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Dianthus Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06858579)) |

## Drugs

- [Batoclimab](https://sec-api.dev/pdufa/batoclimab) (IMVT)
- [Batoclimab 680 milligrams (mg) subcutaneous (sc) weekly](https://sec-api.dev/pdufa/batoclimab-680-milligrams-mg-subcutaneous-sc-weekly) (IMVT)
- [Riliprubart](https://sec-api.dev/pdufa/riliprubart) (SNY)
- [Imeroprubart](https://sec-api.dev/pdufa/imeroprubart) (IMVT)
- [Claseprubart](https://sec-api.dev/pdufa/claseprubart) (DNTH)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/chronic-inflammatory-demyelinating-polyneuropathy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Chronic Inflammatory Demyelinating Polyneuropathy FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/chronic-inflammatory-demyelinating-polyneuropathy

```bibtex
@misc{secapidev_indications_chronic_inflammatory_demyelinating_polyneuropathy_20261116,
  title        = {Chronic Inflammatory Demyelinating Polyneuropathy FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/chronic-inflammatory-demyelinating-polyneuropathy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_chronic_inflammatory_demyelinating_polyneuropathy_20261116","title":"Chronic Inflammatory Demyelinating Polyneuropathy FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/chronic-inflammatory-demyelinating-polyneuropathy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
